When I was a kid, I had one of those toy doctor kits with a plastic stethoscope that made me feel like I could handle anything from a scraped knee to, presumably, the collapse of modern civilization. Adult medicine is less adorable. Chronic lymphocytic leukemia, or CLL, is a good example: we have much better tools now, but the disease still keeps slipping out the back like a movie villain who somehow survives the explosion.
That is the tension at the center of a new Blood paper, “Unfinished Business in Chronic Lymphocytic Leukemia: Translational and Clinical Priorities for a Cure.” The title is basically CLL saying, "Cute progress. I remain employed." The authors argue that while targeted drugs have changed life for many patients, a true cure is still rare - especially for people with high-risk disease, drug resistance, or Richter transformation, when CLL morphs into a much more aggressive lymphoma.[1]
The plot twist: this leukemia messes with the security team
CLL is a cancer of B cells, which are part of your immune system. That already makes things weird. It is like finding out the building's security staff has also been forwarding key-card access to the burglars.
Over the last decade, treatments that block BTK and BCL2 have been a huge deal. In plain English, they cut off survival signals that CLL cells use to keep hanging around like uninvited party guests who somehow know where the snacks are.[2] Patients often live longer and do better on these drugs than they did with older chemo-heavy approaches.
But this paper's point is not "look how far we've come, cue inspirational piano." It is more: "Nice work. Why is the hard part still hard?"
One reason is that CLL is not one disease wearing one outfit. It is more like a franchise with too many spinoffs. Some cases move slowly for years. Others get aggressive, dodge treatment, or come back with new tricks. Patients with TP53 disruption, resistance to both BTK and BCL2 inhibitors, or Richter transformation still face especially rough odds.[1,3,4]
CLL is not just cancer. It's cancer plus immune chaos
One of the most interesting points in the paper is that CLL should also be understood as a disease of immune dysfunction. That came into brutal focus during the COVID era, when patients with CLL often had poor outcomes and weaker protection from infection.
This matters because even when you control the leukemia, the immune system may still be off its game. People with CLL can have low antibody levels, higher infection risk, autoimmune complications, and more secondary cancers.[5,6] So the medical problem is not just "kill the leukemia cells." It is also "can we repair the neighborhood after years of terrible management?"
That question could shape the future of treatment. If researchers learn how CLL rewires immune cells and the tumor microenvironment, they may be able to do more than hold the disease at bay. They might restore immune function, prevent complications, and maybe set up combinations that push more patients toward long-term remission that actually sticks.
Why the cure conversation is still awkward
There is another challenge here: measurable residual disease, or MRD. That is the tiny amount of leukemia that can remain after treatment even when scans and bloodwork look great. Think of it as the horror-movie hand reaching out of the grave right when you thought the credits were rolling.[7]
MRD has become a big deal in CLL because it helps doctors see who has a deeper response and who may be at higher risk of relapse. But using MRD to guide treatment perfectly is still a work in progress. Same for figuring out which patients need continuous therapy, which ones might benefit from time-limited combinations, and which escape routes the cancer is already building behind the drywall.[2,7]
Meanwhile, the field keeps moving. Newer approaches such as non-covalent BTK inhibitors were designed specifically to get around some resistance mutations, and recent FDA action on pirtobrutinib shows how fast this chess match is evolving.[8] That is encouraging. It is also a reminder that CLL researchers are not playing checkers against a sleepy opponent. They are playing speed chess against a disease that keeps changing the rules mid-game.
Why this paper matters outside CLL too
This is where the article gets bigger than leukemia. CLL is a useful test case for a modern cancer question: what do you do when you can control a disease for years, but not consistently erase it?
The answer probably will not come from one magic drug descending from the heavens like Gandalf with a prescription pad. It will come from mixing molecular biology, immune science, resistance tracking, and smarter clinical trial design. If that sounds less cinematic than a miracle cure, fair enough. But it is how real progress usually works.
And if researchers pull it off in CLL, the lessons could spill into other cancers where the enemy is not just the tumor, but the whole messed-up ecosystem around it.
References
-
Wu CJ, Caligaris-Cappio F, Chiorazzi N, Gribben JG, Hallek MJ, Wierda WG, Kipps TJ. Unfinished Business in Chronic Lymphocytic Leukemia: Translational and Clinical Priorities for a Cure. Blood. 2026. DOI: 10.1182/blood.2025032393
-
Stanchina MD, Montoya S, Danilov AV, et al. Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nat Rev Clin Oncol. 2024;21(12):867-887. DOI: 10.1038/s41571-024-00956-1
-
Wiśniewski K, Puła B. A Review of Resistance Mechanisms to Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia. Int J Mol Sci. 2024;25(10):5246. DOI: 10.3390/ijms25105246
-
Parry EM, Ten Hacken E, Wu CJ. Richter syndrome: novel insights into the biology of transformation. Blood. 2023;142(1):11-22. DOI: 10.1182/blood.2022016502
-
Mikulska M, Oltolini C, Zappulo E, et al. Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines. Blood Rev. 2024;65:101180. DOI: 10.1038/s41408-024-01107-6
-
Wikipedia contributors. Chronic lymphocytic leukemia. Wikipedia. Accessed May 7, 2026. https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia
-
Rios-Olais FA, Hilal T. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice. Curr Treat Options Oncol. 2023;24(8):907-928. DOI: 10.1007/s11864-023-01103-1
-
U.S. Food and Drug Administration. FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma. December 1, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.